Porcine endogenous retroviruses (PERVs) are present in the genomes of pig cells. The PERV-A/C recombinant virus can infect human cells and is a major risk of zoonotic disease in the case of xenotransplantation of pig organs to humans. Raltegravir (RAL) is a viral integrase (IN) inhibitor used in highly active antiretroviral treatment. In the present study, we explored the potential use of RAL against PERV-A/C. We report (i) a three-dimensional model of the PERV-A/C intasome complexed with RAL, (ii) the sensitivity of PERV-A/C IN to RAL in vitro and (iii) the sensitivity of a PERV-A/C-IRES-GFP recombinant virus to RAL in cellulo. We demonstrated that RAL is a potent inhibitor against PERV-A/C IN and PERV-A/C replication with IC 50 s in the nanomolar range. To date, the use of retroviral inhibitors remains the only way to control the risk of zoonotic PERV infection during pig-to-human xenotransplantation.
Porcine Endogenous retrovirus (PERV) is a member of the genus Gammaretrovirus and comprises three subtypes: PERV-A, -B and -C. The PERV-A/C recombinant virus has been shown to infect human cells in vitro (Patience et al., 1997) . Thus, the risk of zoonotic transmission has raised serious biosafety concerns about the use of pig organs in human xenotransplantation programmes (Kimsa et al., 2014) .
In the latest release of the pig genome (Sus scrofa version 10.2; GCA_000003025.4), a thorough full analysis of the PERV integration loci revealed the absence of intact fulllength sequences and a considerable polymorphism in PERV loci between different pigs (Groenen et al., 2012) , making the genetic selection of PERV-free pigs unlikely. Furthermore, it was observed that through complementation and genetic recombination, two defective PERV genomes could give rise to an infectious virus such as the PERV-A/C recombinant virus (Bartosch et al., 2004; Martin et al., 2006) .
Finding drugs that could be used against PERV replication is therefore highly desirable. Several drugs have been developed against human immunodeficiency virus type 1 (HIV-1) and susceptibility of PERV was demonstrated in vitro to the triphosphorylated nucleoside analogue of zidovudine (AZT). However, no inhibition of PERV was observed with several other drugs directed against HIV-1 ( Qari et al., 2001; Stephan et al., 2001; Wilhelm et al., 2002) .
A critical step for retroviral replication is the stable integration of the provirus into the host genome. The viral enzyme integrase (IN) has a key role in this event . Previously, we characterized the integration profile of PERV-A/C in human cells and demonstrated that the integration profile of PERV-A/C showed an affinity for transcription start sites and CpG islands, and displayed common patterns of target site preference with both murine leukemia virus (MLV), another gammaretrovirus (Moalic et al., 2006 (Moalic et al., , 2009 , and the prototype foamy virus (PFV), a spumavirus (Mitchell et al., 2004; Nowrouzi et al., 2006; Trobridge et al., 2006) . In human gene therapy protocols, the use of MLV-based vectors was associated with a high mutagenic insertion risk (HaceinBey-Abina et al., 2003) . PERV, which is otherwise insensitive to restriction by TRIM5a molecules (Wood et al., 2009) , is probably associated with the same risk.
Raltegravir (RAL) was the first IN inhibitor to be approved in 2007 for the treatment of HIV-1 infections. Elvitegravir and dolutegravir were approved recently. These compounds act as IN strand transfer (ST) inhibitors (INSTIs) (Serrao et al., 2009) and display varying efficiency depending on the retrovirus (Koh et al., 2011) .
Here, we built a three-dimensional model of the PERV-A/C intasome (IN with viral DNA) in complex with RAL. We explored the potential use of RAL against PERV-A/C IN in vitro and against a PERV-A/C replication-competent virus in cellulo.
INs are modular proteins composed of three functional domains: the N-terminal domain (NTD), the catalytic core domain (CCD) and the C-terminal domain (CTD) (Fig. 1a) . The individual structures of these domains have been characterized for many retroviruses (Jaskolski et al., 2009) , but not for PERV. Within the gammaretroviruses, PERV-A/C IN is closely related to MLV IN, sharing 50 % sequence identity in total, with 22 % for the NTD, 72 % for the CCD and 50 % for the CTD. PERV-A/C IN also shares a significant 26 % sequence identity with PFV IN, whose full-length structure is known (Hare et al., 2010a; Maertens et al., 2010) . Sequence identity is lower with the HIV-1 and alpharetrovirus Rous-associated virus type 1 (RAV-1) INs at 17 and 18 % identity, respectively (Fig. 1b ). (Vagin et al., 2004) (for structure quality assessment, see Table S1 , available in the online Supplementary Material). The resulting PERV-A/C IN model can be superimposed with the crystal structure of PFV IN (Fig. 1c) with a root-mean-square deviation of 2.1 Å on 324 Ca pairs. A model of the full-length HIV-1 IN was previously proposed by using a similar method (Krishnan et al., 2010) .
The crystal structure of the PFV intasome complexed with RAL (PDB ID: 3OYA) (Hare et al., 2010b ) was used to position bound RAL and viral DNA in our PERV-A/C IN model, after optimal superposition with the graphics program Coot (Emsley et al., 2010) . The resulting model of the PERV-A/C IN : RAL intasome was energy minimized with REFMAC5 (Table S1 , Fig. 1c) . The RAL-binding site of PFV is composed of residues Asp131, Asp188, Tyr215 and Pro217. These four residues are strictly conserved in PERV-A/C IN (corresponding to Asp124, Asp183, Tyr210 and Pro212) and well conserved in HIV-1 IN (Fig. 1b) . Thus, PERV-A/C IN is expected to bind RAL, and a similar sensitivity to INSTIs is expected in spumaviruses, gammaretroviruses and lentiviruses. However, PFV Tyr215 and Pro217 are substituted by Gly and Ser in alpharetroviruses (Fig. 1a) , giving rise to a significant resistance of Rous sarcoma virus IN against elvitegravir (Koh et al., 2011) .
We tested the sensitivity of PERV-A/C IN to RAL in vitro. We cloned and purified a recombinant PERV-A/C IN as we previously did for RAV-1 (Moreau et al., 2002 (Moreau et al., , 2003 (Moreau et al., , 2004 (Moreau et al., , 2009 Charmetant et al., 2011) and HIV-1 INs (Cellier et al., 2013; Trabaud et al., 2015) . The PERV IN coding sequences were subcloned into the pET14b plasmid and expressed as an N-terminal His 6 -tagged protein in Escherichia coli. Purification was performed according to protocols previously developed for MLV (Jonsson et al., 1993; Yang et al., 1999) . IN proteins expressed in bacteria were routinely purified to .90 % purity (Fig. S1 ). PERV-A/C IN activities (39 processing and ST) were tested in vitro (Fig. S2) and IN was further assayed for its sensitivity to the ST inhibitor RAL (supplied by the National Institutes of Health AIDS Research and Reference Reagent Program). The IC 50 was determined in a dose-response assay. We tested the drug from 1 nM to 10 mM and reported the ST activity as a percentage of the activity obtained in the absence of the drug (between 1 and 400 nM in Fig. 2) . ST activity was almost completely inhibited at concentrations .400 nM and RAL inhibited the ST activity of the purified PERV-A/C IN in vitro with an IC 50 of 40 nM. In parallel, RAL inhibited the ST activity of a purified HIV-1 IN (Cellier et al., 2013) with an IC 50 of 9 nM (data not shown), in accordance with other data (Bar-Magen et al., 2009) . These data showed that the RAL inhibitor can effectively inhibit PERV-A/C IN at concentrations that were similar to those needed for the inhibition of HIV-1 IN activity.
Finally, we constructed a replication-competent PERV-A/C virus encoding the GFP marker and used it to determine the susceptibility of PERV-A/C to RAL. A molecular clone of PERV-A/C (AY570980) expressing the GFP marker (PERV-A/C-IRES-GFP) was constructed to monitor the infection process. The GFP sequence was inserted downstream of an internal ribosome entry site (IRES) sequence (Fig. 3a) . Transfections, virus preparation and cell infections were performed as described previously (Moalic et al., 2009) . + cells was close to 20 % for both constructs. This percentage decreased to a fluorescence background level for the integration-defective PERV-A/C, whereas it remained stable for the next 2 weeks with the GFP integration-and replication-competent construction. Then, the percentage of GFP + cells increased progressively to reach 100 % GFP + cells after 1 month (Fig. 3b ). concentrations varying from 0.001 to 10 mM per well. At 48 h after infection, the percentage of GFP + cells displayed a twofold decrease with the first RAL concentration (0.001 mM) compared with the infected but RAL-untreated cells (Fig. 3c ). This decrease of infected cells intensified with the range of drug and reached the concentration required to inhibit viral replication by 95 % at 0.1 mM. The EC 50 could be estimated as 1 nM RAL, which is similar to the EC 50 estimated for MLV (4.2¡0.1 nM) and HIV-1 (8.4¡2.8 nM) (Koh et al., 2011) . We also showed that the level of 2LTRc, which represents abortive integration events, was 7.7 times higher in cells treated with 1 mM RAL than in untreated but infected cells (data not shown). Thus, the activity profile of RAL on the replication of PERV-A/C-IRES-GFP appeared similar to that of MLV and HIV-1. 
